Spectrum Pharmaceuticals received Fast Track designation from the FDA for apaziquone in bladder cancer. Fast Track is designed to facilitate drug development and expedite the review of drugs intended to treat serious conditions and demonstrate the potential to address unmet medical needs. “We are pleased that the FDA has accepted apaziquone for bladder cancer under its Fast Track program,” said Rajesh C. Shrotriya, M.D., chairman, president, and chief executive officer of Spectrum. “In a mar...